# Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

> **NCT00861601** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 38 (actual)

## Conditions studied

- Liver Diseases

## Interventions

- **DRUG:** eltrombopag 12.5 milligrams (mg) tablet
- **DRUG:** eltrombopag 25 mg tablet

## Key facts

- **NCT ID:** NCT00861601
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861601, "Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00861601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*